Balancing Innovation, Access, and Profits -- Market Exclusivity for Biologics.

被引:42
作者
Engelberg, Alfred B. [1 ]
Kesselheim, Aaron S. [2 ,3 ]
Avorn, Jerry [2 ,3 ]
机构
[1] Engelberg Fdn, Palm Beach, FL 33480 USA
[2] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
关键词
D O I
10.1056/NEJMp0908496
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:1917 / 1919
页数:3
相关论文
共 4 条
[1]   Scientific and legal viability of follow-on protein drugs [J].
Dudzinski, David M. ;
Kesselheim, Aaron S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (08) :843-849
[2]  
Engelberg AlfredB., 1999, IDEA J LAW TECHNOLOG, V39, P389
[3]  
*FED TRAD COMM, 2009, FOLL ON BIOL DRUG CO
[4]  
SYRE S, 2009, BOSTON GLOBE 0821